Doc code: IDS Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number		10752423	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Filing Date		2004-01-06	
	First Named Inventor	Erik B	Buntinx	
	Art Unit		1617	
	Examiner Name	Rama	chandran, Umamaheswari	
	Attorney Docket Number		29248-19	

U.S.PATENTS										
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D)ate	of cited Document		Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear		
/U.R./	1	5554383		1996-09	ı-10	Dodman				
/U.R./	2	5762960		1998-06	i-09	Dodman				
/U.R./	3	5759837		1998-06	i-02	Kuhajda et al.				
If you wisl	n to ac	ld additional U.S. Pater	nt citatio	n inform	ation pl	ease click the	Add button.			
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS			
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication 1 Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wisl	n to ac	ld additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Ado	d butto	on.	
				FOREIG	SN PAT	ENT DOCUM	ENTS			
Examiner Initial*	Cite No	Foreign Document Number ³	Country Kind Code ² i Code ⁴		Publication Date	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T 5	
/U.R./	1	4039631	DE	E A1		1992-06-17	Dr. Kerstin Bode-Greuel		Abstract	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10752423		
Filing Date		2004-01-06		
First Named Inventor	Erik Buntinx			
Art Unit		1617		
Examiner Name	Ramachandran, Umamaheswari			
Attorney Docket Number		29248-19		

/\	J.R./	2	2461248	CA		2009-09-08	Pharmaneuroboost N.V.	Notice of Allowance	
/U.R./ 3 0141701 WO		A2	2001-06-14	Cremers					
If y	ou wis	h to a	dd additional Foreign P	atent Document	citation	information pl	ease click the Add butto	n	
				NON-PATE	NT LITE	RATURE DO	CUMENTS		
Examiner Initials* Cite No Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.								T 5	
/L	J.R./	1	USPTO Office Action dated 06/10/2009 in connection with related Application Serial No. 10/725,965 filed 12/02/2003, Examiner Umamaheswari Ramachandran, Art Unit 1617.						
		2	USPTO Office Action dated 11/10/2009 in connection with related Application Serial No. 10/803,793 filed 03/18/2004, Examiner Benjamin J. Packard, Art Unit 1612.						
		3	USPTO Office Action dated 07/21/2009 in connection with related Application Serial No. 10/984,683 filed 11/09/2004, Examiner Anna Pagonakis, Art Unit 1614.						
		4	USPTO Office Action dated 06/02/2009 in connection with related Application Serial No. 10/580,962 filed 5/31/2006, Examiner Sarah Pihonak, Art Unit 1617.						
		5	NELSON, Craig J., et al., "Atypical Antipsychotic Augmentation in Major Depressive Disorder: A Meta-Analysis of Placebo-Controlled Randomized Trials." Am J Psychiatry, September 2009, 166:980-991.						
		6	PEREMANS, Kathelijne et al., "Evaluation of serotonin-2A receptor occupancy with 123 I-5-I-R91150 and single-photon emission tomography before and after low-dose pipamperone administration in the canine brain." Nuclear Medicine Communications, 29:724-729, 2008.						
e de la constante de la consta	/	7	Download from www.whocc.no/atcddd/welcome.html dated 08/20/2009, 2 pages.						

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10752423		
Filing Date		2004-01-06		
First Named Inventor	Erik Buntinx			
Art Unit		1617		
Examiner Name	Ramachandran, Umamaheswari			
Attorney Docket Number		29248-19		

/U.R./	8	BUNTINX, E. et al., 'Preclinical and clinical evidence for the efficacy of pipamperone in augmenting the antidepressant effects of the SSRI citalopram." International Journal of Neuropsychopharmaccology, volume 1, supplement 1, p. 190, July 2008.						
000000000000000000000000000000000000000	9	BUNTINX E et al., Preclinical and Clinical Evidence for the Efficacy of Pipamperone in Augmenting the Antidepressant Effects of the SSRI Citalopram." Poster presented at the XXVI Collegium Internationale Neuro-Psychopharmacologicum (CINP) Congress 13-17 July 2008, Munich, Germany and Summary Expected Receptor Occupancy (RO) of Pipamperone in vivo.						
V	10	Download, "Panic Attacks Anxiety Attacks Self-Help Anxieties OCD Social Anxiety Disorder." http://www.anxieties.com/med-intro.php, December 3, 2009, pp. 1-5.						
If you wis	sh to a	dd additional non-patent literature document citation information please click	the Add b	outton				
EXAMINER SIGNATURE								
Examiner Signature /Umamaheswari Ramachandran/ Date Considered 03/11/2010								
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								
¹ See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.								